Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
HC Surgical Specialists Limited (1B1.SI)
Singapore, SG
HC Surgical Specialists Limited, an investment holding company, primarily delivers a diverse spectrum of medical services across Singapore. Through its network of clinics, the company specializes in endoscopic procedures, such as gastroscopies and colonoscopies, in addition to providing general surgical services with a notable focus on colorectal issues. Their expertise further extends to treating a variety of conditions, including haemorrhoids, anal fissures, hernias, anal abscesses, cholecystitis, anal fistulas, appendicitis, colorectal and gastric cancers, lipomas, and cysts, utilizing advanced techniques like vein laser vascular therapy and laparoscopy. Moreover, the company offers extensive orthopedic services. These address concerns such as joint pain, sports injuries, osteoarthritis, rotator cuff tears, trigger finger, tenosynovitis, tunnel syndrome, and various wounds or lumps. Surgical interventions include joint replacements, arthroscopic procedures, knee osteotomy, realignment surgery, endoscopic spine surgery, disc replacements, spinal decompression, and fracture management, supported by orthobiologic injections. Beyond clinical care, the company provides comprehensive home care services, encompassing medical, nursing, physiotherapy, speech, occupational therapy, and ambulance support. Their community health initiatives include health screenings, management of acute and chronic conditions, pre-employment check-ups, and participation in public health schemes such as the 'swab and send home' program, the community health assist scheme, and COVID-19 testing. To support accurate diagnosis, a full array of diagnostic tests is available, including blood work, X-rays, ultrasounds, CT scans, and MRIs. The company was founded in Singapore in 2015, where it continues to be headquartered.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.70% | +0.00% | +0.00% | +7.04% | +11.76% | +4.11% | +33.33% | -3.80% | -20.83% | -34.48% | -34.48% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
-
Revenue growth Medical - Diagnostics & Research: +7.9%+1.6% Q2'25: +0.1% (vs Q2'24)
-
EPS growth Medical - Diagnostics & Research: +30.8%+117.0% ★ Q2'25: +1,169.2% (vs Q2'24)
-
FCF margin FCF growth · Medical - Diagnostics & Research: +32.2%+53.7% ★ Q2'25: +37.6% (vs Q2'24)
-
EBIT margin Medical - Diagnostics & Research: +9.6%+46.8% ★ Q2'25: +24.7% (vs Q2'24)
-
ROIC Medical - Diagnostics & Research: +5.2%+50.1% ★ Q2'25: +25.1% (vs Q2'24)
-
Share dilution Medical - Diagnostics & Research: 0.0%+0.9% Q2'25: -0.1% (vs Q2'24)
-
Debt / EBITDA Net debt/EBITDA · Medical - Diagnostics & Research: -0.13×0.26× ★ Q2'25: 0.55× (vs Q2'24)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-28 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-25 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-22 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-21 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-19 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-18 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-15 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-13 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-07 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 3/5 | 4/5 | 3/5 |
| 2026-05-05 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 2/5 | 4/5 | 3/5 |
| 2026-05-04 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 2/5 | 4/5 | 3/5 |
| 2026-04-30 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 2/5 | 4/5 | 3/5 |
| 2026-04-28 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 2/5 | 4/5 | 3/5 |
| 2026-04-27 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 2/5 | 4/5 | 3/5 |
| 2026-04-21 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-20 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-16 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Sieu Min Heah FAMS Surgen FRCSEd BCh | Chief Executive Officer & Executive Director | 1M | — |
| Kok Hoong Chia FAMS FRCSEd MBBS | Medical Director & Executive Director | 646.6K | — |
| Josephine Tio Melissa | Chief Operating Officer | — | female |
| Moi Heyang Lin ACIS | Joint Company Secretary | — | female |
| Pei Chan Tang ACIS | Joint Company Secretary | — | female |
| Gary Ng | Head of the Internal Audit | — | male |
| Soo Ling Ong | Chief Financial Officer | — | female |
| Hui Theng Lee | Chief Nursing Officer | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 1B1.SI
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
